Scinai Immunotherapeutics Awarded Grant to Support New CDMO Biz

Scinai Immunotherapeutics Ltd. was awarded a grant from the Israel Innovation Authority (IIA) covering 66% of the costs of an approximately $900,000 project aimed at ramping up Scinai’s new CDMO business unit. The grant is neither subject to repayment nor tied to royalty payments.
 
Scinai’s research and development capabilities specialize in developing innovative inflammation and immunology biologics to combat autoimmune and infectious diseases. Scinai’s CDMO services provide tailored drug development and GMP manufacturing for clinical trials.
 
The IIA chose Scinai’s capabilities to fill an underserved need in Israel’s pharmaceutical R&D ecosystem. In particular, the IIA believes that Scinai’s state-of-the-art GMP biologics manufacturing facility and adjacent R&D and QC labs are well-positioned to provide highly sought-after R&D and manufacturing services.
 
The new business unit, Scinai Bioservices, provides biopharmaceutical clients in Israel and globally with manufacturing process development for protein-based drugs, including host cell transfection / transformation, upstream and downstream process development and scale-up, analytical method development, and cGMP manufacturing for clinical trial supplies, including automatic aseptic filling.
 
Amir Reichman, Scinai’s CEO, said, “I thank the IIA for its support of Scinai’s plans and their concrete belief in the potential of our business to generate value for stakeholders. This meaningful grant will not only advance our CDMO business unit, but also provide much needed relief to our financial position, thereby also indirectly helping our R&D business unit’s drive towards developing our innovative NanoAb-based drug pipeline and clearing the path towards developing Scinai into a company that provides significant benefits to the local and global biopharma industry.”